Intensity Therapeutics (INTS) to Post Earnings on Thursday

Intensity Therapeutics (NASDAQ:INTS) will likely be announcing its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect Intensity Therapeutics to announce earnings of ($0.8725) per share for the quarter. Investors may review the information on the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Wednesday, August 5, 2026 at 4:00 PM ET.

Intensity Therapeutics (NASDAQ:INTS) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($0.96) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.08) by $0.12. On average, analysts expect Intensity Therapeutics to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Intensity Therapeutics Stock Performance

Shares of Intensity Therapeutics stock opened at $4.33 on Thursday. The firm has a market cap of $11.69 million, a P/E ratio of -0.76 and a beta of 2.78. The company has a current ratio of 4.86, a quick ratio of 4.86 and a debt-to-equity ratio of 0.01. Intensity Therapeutics has a 12 month low of $3.51 and a 12 month high of $43.50. The stock’s fifty day moving average price is $4.30 and its 200-day moving average price is $6.03.

Analysts Set New Price Targets

INTS has been the subject of a number of research reports. Wall Street Zen raised shares of Intensity Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, April 4th. Weiss Ratings reissued a “sell (e+)” rating on shares of Intensity Therapeutics in a research report on Tuesday, July 21st. Finally, Benchmark restated a “speculative buy” rating on shares of Intensity Therapeutics in a report on Wednesday, May 20th. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Intensity Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $37.50.

Institutional Investors Weigh In On Intensity Therapeutics

Large investors have recently made changes to their positions in the stock. Geode Capital Management LLC lifted its position in Intensity Therapeutics by 77.8% during the 4th quarter. Geode Capital Management LLC now owns 460,248 shares of the company’s stock worth $189,000 after acquiring an additional 201,357 shares during the period. Jane Street Group LLC acquired a new position in shares of Intensity Therapeutics in the fourth quarter valued at about $26,000. State Street Corp raised its stake in shares of Intensity Therapeutics by 839.3% in the fourth quarter. State Street Corp now owns 136,200 shares of the company’s stock worth $56,000 after purchasing an additional 121,700 shares during the last quarter. Finally, Corient Private Wealth LLC acquired a new stake in shares of Intensity Therapeutics during the fourth quarter worth about $41,000. 3.74% of the stock is owned by hedge funds and other institutional investors.

About Intensity Therapeutics

Intensity Therapeutics, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. The company's lead product candidate is INT230-6, which is in Phase 2 clinical trial for the treatment of refractory solid tumors; and pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers. It has a collaboration agreement with Merck Sharpe & Dohme Corp. to evaluate the combination of INT230-6 and Keytruda in patients with advanced pancreatic, colon, squamous cell, and bile duct malignancies; Bristol-Myers Squibb Company to evaluate the combination of INT230-6 with Yervoy in patients with advanced liver, breast, and sarcoma cancers; and Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research to study INT230-6 in a randomized controlled neoadjuvant phase II study in women with early-stage breast cancer.